Fig. 1 | Scientific Reports

Fig. 1

From: Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3

Fig. 1

(a) RdRp DENV-3 (a) RMSD values of the Cromolyn-RdRp, Empagliflozin-RdRp, Lumacaftor-RdRp, Netarsudil-RdRp, ZINC13375652-RdRp, ZINC14679204-RdRp, ZINC85491556-RdRp, ZINC85510542-RdRp complexes and unbonded RdRp. (b) Rg values of the Cromolyn-RdRp, Empagliflozin-RdRp, Lumacaftor-RdRp, Netarsudil-RdRp, ZINC13375652-RdRp, ZINC14679204-RdRp, ZINC85491556-RdRp, ZINC85510542-RdRp complexes and unbonded RdRp. (c) The RMSF values of the Cromolyn-RdRp, Empagliflozin-RdRp, Lumacaftor-RdRp, Netarsudil-RdRp, ZINC13375652-RdRp, ZINC14679204-RdRp, ZINC85491556-RdRp, ZINC85510542-RdRp complexes and unbonded RdRp. (d) The Hbond values of the Cromolyn-RdRp, Empagliflozin-RdRp, Lumacaftor-RdRp, Netarsudil-RdRp, ZINC13375652-RdRp, ZINC14679204-RdRp, ZINC85491556-RdRp, and ZINC85510542-RdRp complexes.

Back to article page